765100login-checkMid-Stage Win for Novel IgA Nephropathy Drug |
— APRIL-neutralizing antibody sibeprenlimab reduced proteinuria and stabilized eGFR
By Kristen Monaco
PHILADELPHIA — An investigational humanized IgG2 monoclonal antibody reduced proteinuria in adults with immunoglobulin A (IgA) nephropathy at high risk for disease progression despite standard treatments, a randomized phase II trial found.
In a dose-dependant manner, intravenous sibeprenlimab led to significantly greater decreases in 24-hour urinary protein-to-creatinine ratio at 12 months compared with placebo, with geometric mean ratio reductions ranging from 47.2% to 62% versus 20%, respectively (P<0.001), meeting the trial’s primary endpoint, reported Mohit Mathur, MD, of drugmaker Visterra in Waltham, Massachusetts. Read the full article in MedPage Today.
765100login-checkMid-Stage Win for Novel IgA Nephropathy Drug |